Shares of Moderna Inc.
MRNA,
+17.10%
were up 9.4% in trading on Monday after the company said its COVID-19 vaccine has been granted a provisional authorization in Australia to adults who are at least 18 years old. Australia has purchased 10 million doses of Moderna’s vaccine for 2021 and has the option to purchase an additional 15 million doses in 2022. Moderna said it expects to begin delivering doses of the vaccine in September. Moderna’s stock has soared 333.9% so far this year, while the S&P 500
SPX,
-0.09%
is up 18.1%.

Source link